-
1
-
-
84952980031
-
Pyrimidinediamine kinase inhibitors
-
Rigel Pharmaceuticals, Inc. US 2010179134, WO 2010078369
-
Singh, R., Atuegbu, A., Ramphal, J. et al. (Rigel Pharmaceuticals, Inc.). Pyrimidinediamine kinase inhibitors. US 2010179134, WO 2010078369.
-
-
-
Singh, R.1
Atuegbu, A.2
Ramphal, J.3
-
2
-
-
84952989344
-
Synthesis of N4-(2,2-dimethyl-4-[dihydrogen phosphonoxy]-3-oxo-5- pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2, 4-pyrimidinediamine disodium salt
-
Rigel Pharmaceuticals, Inc.. US 2011003986, WO 2011002999
-
Felfer, U., Giselbrecht, K.-H., Wolberg, M. (Rigel Pharmaceuticals, Inc.). Synthesis of N4-(2,2-dimethyl-4-[dihydrogen phosphonoxy]-3-oxo-5- pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2, 4-pyrimidinediamine disodium salt. US 2011003986, WO 2011002999.
-
-
-
Felfer, U.1
Giselbrecht, K.-H.2
Wolberg, M.3
-
3
-
-
80052960249
-
Prodrug salts of 2,4-pyrimidinediamine compounds and their uses
-
Rigel Pharmaceuticals, Inc. EP 2078026, JP 2010510322, WO 2008064274
-
Bhamidipati, S., Singh, R., Sun, T., Masuda, E. (Rigel Pharmaceuticals, Inc.). Prodrug salts of 2,4-pyrimidinediamine compounds and their uses. EP 2078026, JP 2010510322, WO 2008064274.
-
-
-
Bhamidipati, S.1
Singh, R.2
Sun, T.3
Masuda, E.4
-
4
-
-
80052960249
-
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
-
Rigel Pharmaceuticals, Inc.. CA 2591948, EP 1856135, EP 2161275, JP 2008527048, US 2006211657, US 7449458, WO 2006078846
-
Singh, R., Bhamidipati, S., Masuda, E., Stella, V.J., Sun, T. (Rigel Pharmaceuticals, Inc.). Prodrugs of 2,4-pyrimidinediamine compounds and their uses. CA 2591948, EP 1856135, EP 2161275, JP 2008527048, US 2006211657, US 7449458, WO 2006078846.
-
-
-
Singh, R.1
Bhamidipati, S.2
Masuda, E.3
Stella, V.J.4
Sun, T.5
-
5
-
-
80052960249
-
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
-
Rigel Pharmaceuticals, Inc.. US 7563892
-
Singh, R., Bhamidipati, S., Stella, V.J., Sun, T. (Rigel Pharmaceuticals, Inc.). Prodrugs of 2,4-pyrimidinediamine compounds and their uses. US 7563892.
-
-
-
Singh, R.1
Bhamidipati, S.2
Stella, V.J.3
Sun, T.4
-
6
-
-
0025946132
-
Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis
-
Taniguchi, T., Kobayashi, T., Kondo, J. et al. Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem 1991, 266(24): 15790-6. (Pubitemid 21907727)
-
(1991)
Journal of Biological Chemistry
, vol.266
, Issue.24
, pp. 15790-15796
-
-
Taniguchi, T.1
Kobayashi, T.2
Kondo, J.3
Takahashi, K.4
Nakamura, H.5
Suzuki, J.6
Nagai, K.7
Yamada, T.8
Nakamura, S.-I.9
Yamamura, H.10
-
7
-
-
0033997615
-
Tyrosine kinase SYK: Essential functions for immunoreceptor signalling
-
DOI 10.1016/S0167-5699(99)01574-1, PII S0167569999015741
-
Turner, M., Schweighoffer, E., Colucci, F., Di Santo, J.P., Tybulewicz, V.L. Tyrosine kinase SYK: Essential functions for immunoreceptor signalling. Immunol Today 2000, 21(3): 148-54. (Pubitemid 30122705)
-
(2000)
Immunology Today
, vol.21
, Issue.3
, pp. 148-154
-
-
Turner, M.1
Schweighoffer, E.2
Colucci, F.3
Di, S.J.P.4
Tybulewicz, V.L.5
-
8
-
-
77952887713
-
The SYK tyrosine kinase: A crucial player in diverse biological functions
-
Mocsai, A., Ruland, J., Tybulewicz, V.L. The SYK tyrosine kinase: A crucial player in diverse biological functions. Nat Rev Immunol 2010, 10(6): 387-402.
-
(2010)
Nat Rev Immunol
, vol.10
, Issue.6
, pp. 387-402
-
-
Mocsai, A.1
Ruland, J.2
Tybulewicz, V.L.3
-
9
-
-
33751197936
-
R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation
-
Braselmann, S., Taylor, V., Zhao, H. et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 2006, 319(3): 998-1008.
-
(2006)
J Pharmacol Exp Ther
, vol.319
, Issue.3
, pp. 998-1008
-
-
Braselmann, S.1
Taylor, V.2
Zhao, H.3
-
10
-
-
33645867986
-
A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes
-
Cha, H.S., Boyle, D.L., Inoue, T., Schoot, R., Tak, P.P., Pine, P., Firestein, G.S. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 2006, 317(2): 571-8.
-
(2006)
J Pharmacol Exp Ther
, vol.317
, Issue.2
, pp. 571-578
-
-
Cha, H.S.1
Boyle, D.L.2
Inoue, T.3
Schoot, R.4
Tak, P.P.5
Pine, P.6
Firestein, G.S.7
-
11
-
-
67650458526
-
Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia
-
Buchner, M., Fuchs, S., Prinz, G. et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res 2009, 69(13): 5424-32.
-
(2009)
Cancer Res
, vol.69
, Issue.13
, pp. 5424-5432
-
-
Buchner, M.1
Fuchs, S.2
Prinz, G.3
-
12
-
-
41349110211
-
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma
-
DOI 10.1182/blood-2007-07-100115
-
Chen, L.,Monti, S., Juszczynski, P. et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008, 111(4): 2230-7. (Pubitemid 351451430)
-
(2008)
Blood
, vol.111
, Issue.4
, pp. 2230-2237
-
-
Chen, L.1
Monti, S.2
Juszczynski, P.3
Daley, J.4
Chen, W.5
Witzig, T.E.6
Habermann, T.M.7
Kutok, J.L.8
Shipp, M.A.9
-
13
-
-
70349237504
-
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: Specific targeting with a novel spleen tyrosine kinase inhibitor, R406
-
Quiroga, M.P., Balakrishnan, K., Kurtova, A.V. et al., B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: Specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009, 114(5): 1029-37.
-
(2009)
Blood
, vol.114
, Issue.5
, pp. 1029-1037
-
-
Quiroga, M.P.1
Balakrishnan, K.2
Kurtova, A.V.3
-
14
-
-
77952886100
-
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia
-
Buchner, M., Baer, C., Prinz, G. et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood, 2010, 115(22): 4497-506.
-
(2010)
Blood
, vol.115
, Issue.22
, pp. 4497-4506
-
-
Buchner, M.1
Baer, C.2
Prinz, G.3
-
15
-
-
45949094157
-
Costimulation of dectin-1 and DC-SIGN triggers the arachidonic acid cascade in human monocyte-derived dendritic cells
-
Valera, I., et al., Costimulation of dectin-1 and DC-SIGN triggers the arachidonic acid cascade in human monocyte-derived dendritic cells. J Immunol 2008, 180(8): 5727-36.
-
(2008)
J Immunol
, vol.180
, Issue.8
, pp. 5727-5736
-
-
Valera, I.1
-
16
-
-
33645676304
-
Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation
-
Matsubara, S., Koya, T., Takeda, K. et al. Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation. Am J Respir Cell Mol Biol, 2006, 34(4): p. 426-33.
-
(2006)
Am J Respir Cell Mol Biol
, vol.34
, Issue.4
, pp. 426-433
-
-
Matsubara, S.1
Koya, T.2
Takeda, K.3
-
17
-
-
77956417942
-
Therapeutic targeting of Syk in autoimmune diabetes
-
Colonna, L., Catalano, G., Chew, C. et al. Therapeutic targeting of Syk in autoimmune diabetes. J Immunol 2010, 185(3): 1532-43.
-
(2010)
J Immunol
, vol.185
, Issue.3
, pp. 1532-1543
-
-
Colonna, L.1
Catalano, G.2
Chew, C.3
-
18
-
-
77349087551
-
Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in FcepsilonRI-activated RBL-2H3 basophilic cells
-
Sanderson, M.P., Gelling, S.J., Rippmann, J.F., Schnapp, A. Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in FcepsilonRI-activated RBL-2H3 basophilic cells. Cell Immunol 2010, 262(1): 28-34.
-
(2010)
Cell Immunol
, vol.262
, Issue.1
, pp. 28-34
-
-
Sanderson, M.P.1
Gelling, S.J.2
Rippmann, J.F.3
Schnapp, A.4
-
19
-
-
71849102938
-
Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells
-
Krishnan, S., Juang, Y.T., Chowdhury, B. et al. Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol 2008, 181(11): 8145-52.
-
(2008)
J Immunol
, vol.181
, Issue.11
, pp. 8145-8152
-
-
Krishnan, S.1
Juang, Y.T.2
Chowdhury, B.3
-
20
-
-
46749088793
-
An orally bioavailable inhibitor of FLT3 and Syk kinases prevents tumor growth in subcutaneously implanted human tumor xenografts and promotes cell death of FLT3 mutant AML cells
-
thAnnu Meet Am Soc Hematol (December 10-13, Atlanta) 2005 Abst 243
-
thAnnu Meet Am Soc Hematol (December 10-13, Atlanta) 2005], 2005, 106(11): Abst 243.
-
(2005)
Blood
, vol.106
, Issue.11
-
-
Pine, P.R.1
-
21
-
-
67649494454
-
The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets
-
Spalton, J.C., Mori, J., Pollitt, A.Y., Hughes, C.E., Eble, J.A., Watson, S.P. The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets. J Thromb Haemost 2009, 7(7): 1192-9.
-
(2009)
J Thromb Haemost
, vol.7
, Issue.7
, pp. 1192-1199
-
-
Spalton, J.C.1
Mori, J.2
Pollitt, A.Y.3
Hughes, C.E.4
Eble, J.A.5
Watson, S.P.6
-
22
-
-
78649759107
-
The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling
-
Suljagic, M., Longo, P.G., Bennardo, S., Perlas, E., Leone, G., Laurenti, L., Efremov, D.G. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood 2010, 116(23): 4894-905.
-
(2010)
Blood
, vol.116
, Issue.23
, pp. 4894-4905
-
-
Suljagic, M.1
Longo, P.G.2
Bennardo, S.3
Perlas, E.4
Leone, G.5
Laurenti, L.6
Efremov, D.G.7
-
23
-
-
63849309885
-
Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target
-
Young, R.M., Hardy, I.R., Clarke, R.L. et al. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood 2009, 113(11): 2508-16.
-
(2009)
Blood
, vol.113
, Issue.11
, pp. 2508-2516
-
-
Young, R.M.1
Hardy, I.R.2
Clarke, R.L.3
-
24
-
-
65349104905
-
Of mice and men: An open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk
-
Podolanczuk, A., Lazarus, A.H., Crow, A.R., Grossbard, E., Bussel, J.B. Of mice and men: An open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009, 113(14): 3154-60.
-
(2009)
Blood
, vol.113
, Issue.14
, pp. 3154-3160
-
-
Podolanczuk, A.1
Lazarus, A.H.2
Crow, A.R.3
Grossbard, E.4
Bussel, J.B.5
-
25
-
-
30344435280
-
Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness
-
DOI 10.1164/rccm.200503-361OC
-
Matsubara, S., Li, G., Takeda, K. et al. Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am J Respir Crit Care Med 2006, 173(1): 56-63. (Pubitemid 43069788)
-
(2006)
American Journal of Respiratory and Critical Care Medicine
, vol.173
, Issue.1
, pp. 56-63
-
-
Matsubara, S.1
Li, G.2
Takeda, K.3
Loader, J.E.4
Pine, P.5
Masuda, E.S.6
Miyahara, N.7
Miyahara, S.8
Lucas, J.J.9
Dakhama, A.10
Gelfand, E.W.11
-
26
-
-
34547849752
-
Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor
-
DOI 10.1016/j.clim.2007.03.543, PII S1521661607000617
-
Pine, P.R., Chang, B., Schoettler, N. et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol 2007, 124(3): 244-57. (Pubitemid 47247604)
-
(2007)
Clinical Immunology
, vol.124
, Issue.3
, pp. 244-257
-
-
Pine, P.R.1
Chang, B.2
Schoettler, N.3
Banquerigo, M.L.4
Wang, S.5
Lau, A.6
Zhao, F.7
Grossbard, E.B.8
Payan, D.G.9
Brahn, E.10
-
27
-
-
43949092440
-
An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus
-
DOI 10.1002/art.23428
-
Bahjat, F.R., Pine, P.R., Reitsma, A. et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 2008, 58(5): 1433-44. (Pubitemid 351705932)
-
(2008)
Arthritis and Rheumatism
, vol.58
, Issue.5
, pp. 1433-1444
-
-
Bahjat, F.R.1
Pine, P.R.2
Reitsma, A.3
Cassafer, G.4
Baluom, M.5
Grillo, S.6
Chang, B.7
Fei, F.Z.8
Payan, D.G.9
Grossbard, E.B.10
Daikh, D.I.11
-
28
-
-
77954229590
-
Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice
-
Deng, G.M., Liu, L., Bahjat, F.R., Pine, P.R., Tsokos, G.C. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum 2010, 62(7): 2086-92.
-
(2010)
Arthritis Rheum
, vol.62
, Issue.7
, pp. 2086-2092
-
-
Deng, G.M.1
Liu, L.2
Bahjat, F.R.3
Pine, P.R.4
Tsokos, G.C.5
-
29
-
-
77949363952
-
A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis
-
Smith, J., McDaid, J.P., Bhangal, G. et al. A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis. J Am Soc Nephrol 2010, 21(2): 231-6.
-
(2010)
J Am Soc Nephrol
, vol.21
, Issue.2
, pp. 231-236
-
-
Smith, J.1
McDaid, J.P.2
Bhangal, G.3
-
30
-
-
77955622884
-
Spleen tyrosine kinase inhibition prevents tissue damage after ischemia-reperfusion
-
Pamuk, O.N., Lapchak, P.H., Rani, P., Pine, P., Dalle Lucca, J.J., Tsokos, G.C. Spleen tyrosine kinase inhibition prevents tissue damage after ischemia-reperfusion. Am J Physiol Gastrointest Liver Physiol 2010, 299(2): G391-9.
-
(2010)
Am J Physiol Gastrointest Liver Physiol
, vol.299
, Issue.2
-
-
Pamuk, O.N.1
Lapchak, P.H.2
Rani, P.3
Pine, P.4
Dalle Lucca, J.J.5
Tsokos, G.C.6
-
31
-
-
77951002653
-
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
-
Friedberg, J.W., Sharman, J., Sweetenham, J. et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115(13): 2578-85.
-
(2010)
Blood
, vol.115
, Issue.13
, pp. 2578-2585
-
-
Friedberg, J.W.1
Sharman, J.2
Sweetenham, J.3
-
32
-
-
55849114400
-
Treatment of rheumatoid arthritis with a Syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial
-
Weinblatt, M.E., Kavanaugh, A., Burgos-Vargas, R. et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008, 58(11): 3309-18.
-
(2008)
Arthritis Rheum
, vol.58
, Issue.11
, pp. 3309-3318
-
-
Weinblatt, M.E.1
Kavanaugh, A.2
Burgos-Vargas, R.3
-
33
-
-
77953742534
-
Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: Contribution of hepatic and gut bacterial processes to the overall biotransformation
-
Sweeny, D.J., Li, W., Clough, J. et al. Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: Contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab Dispos 2010, 38(7): 1166-76.
-
(2010)
Drug Metab Dispos
, vol.38
, Issue.7
, pp. 1166-1176
-
-
Sweeny, D.J.1
Li, W.2
Clough, J.3
-
34
-
-
34249825194
-
Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406
-
DOI 10.1016/j.taap.2007.03.027, PII S0041008X07001457
-
Zhu, Y., Herlaar, E., Masuda, E.S., Burleson, G.R., Nelson, A.J., Grossbard, E.B., Clemens, G.R. Immunotoxicity assessment for the novel spleen tyrosine kinase inhibitor R406. Toxicol Appl Pharmacol 2007, 221(3): 268-77. (Pubitemid 46855812)
-
(2007)
Toxicology and Applied Pharmacology
, vol.221
, Issue.3
, pp. 268-277
-
-
Zhu, Y.1
Herlaar, E.2
Masuda, E.S.3
Burleson, G.R.4
Nelson, A.J.5
Grossbard, E.B.6
Clemens, G.R.7
-
35
-
-
77957333252
-
An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis
-
Weinblatt, M.E., Kavanaugh, A., Genovese, M.C., Musser, T.K., Grossbard, E.B., Magilavy, D.B. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010, 363(14): 1303-12.
-
(2010)
N Engl J Med
, vol.363
, Issue.14
, pp. 1303-1312
-
-
Weinblatt, M.E.1
Kavanaugh, A.2
Genovese, M.C.3
Musser, T.K.4
Grossbard, E.B.5
Magilavy, D.B.6
-
36
-
-
78650294662
-
An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritisthat did not respond to biologic agents
-
Genovese, M.C., Kavanaugh, A., Weinblatt, M.E. et al. An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritisthat did not respond to biologic agents. Arthritis Rheum 2010, 63(2): 337-45.
-
(2010)
Arthritis Rheum
, vol.63
, Issue.2
, pp. 337-345
-
-
Genovese, M.C.1
Kavanaugh, A.2
Weinblatt, M.E.3
-
37
-
-
62949223071
-
Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing
-
Clemens, G.R., Schroeder, R.E., Magness, S.H. et al. Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing. Birth Defects Res A Clin Mol Teratol 2009, 85(2): 130-6.
-
(2009)
Birth Defects Res A Clin Mol Teratol
, vol.85
, Issue.2
, pp. 130-136
-
-
Clemens, G.R.1
Schroeder, R.E.2
Magness, S.H.3
-
38
-
-
33646674509
-
A multiple dose study of an orally bioavailable inhibitor of Syk-kinase (R406) in human volunteers: Safety, pharmacokinetics, and pharmacodynamics
-
th Annu Sci Meet Am Coll Rheumatol (Nov 12-17, San Diego) 2005 Abst 1864
-
th Annu Sci Meet Am Coll Rheumatol (Nov 12-17, San Diego) 2005] 2005, 52(9): Abst 1864.
-
(2005)
Arthritis Rheum
, vol.52
, Issue.9
-
-
Grossbard, E.1
-
39
-
-
55849100500
-
A phase I randomized, double-blind, placebo-controlled, pharmacokinetic study of R788/406 and methotrexate in sixteen patients with rheumatoid arthritis
-
Abst 939
-
Grossbard, E., Baluom, M., Kivitz, A.J. A phase I randomized, double-blind, placebo-controlled, pharmacokinetic study of R788/406 and methotrexate in sixteen patients with rheumatoid arthritis. Arthritis Rheum 2006, 54(9, Suppl.): Abst 939.
-
(2006)
Arthritis Rheum
, vol.54
, Issue.9 SUPPL.
-
-
Grossbard, E.1
Baluom, M.2
Kivitz, A.J.3
|